From an article, from gilead.com 1694351805

What was announced?

What were the key findings?

How does this compare historically?

What's next for Trodelvy based on these results?

What ongoing late-stage trial is studying this combination?

Read the article: Gilead’s Phase 2 EVOKE-02 Study of Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer